Some brief digital screening tools have demonstrated promise in differentiating amyloid‐positive and tau‐positive MCI patients (as measured by amyloid and tau PET) from MCI without evidence of amyloid or tau accumulation, but they have not been very good at separating healthy controls from people with MCI or prodromal AD.52 The gene discussed is MAPT; the disease is amyloidosis.